The CLEAR trial established lenvatinib plus pembrolizumab as a frontline option in advanced RCC.
Sumanta Kumar Pal, MD, FASCO
Advertisement
Articles by Sumanta Kumar Pal, MD, FASCO
Selecting first-line therapy for advanced clear cell renal cell carcinoma (RCC) increasingly starts with a choice between dual immunotherapy and an immunotherapy plus tyrosine kinase inhibitor (TKI) combination.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5